MARKET

SRZNW

SRZNW

Surrozen Inc
NASDAQ
0.0190
+0.0041
+27.52%
Closed 15:13 12/05 EST
OPEN
0.0149
PREV CLOSE
0.0149
HIGH
0.0190
LOW
0.0125
VOLUME
5.78K
TURNOVER
--
52 WEEK HIGH
1.210
52 WEEK LOW
0.0010
MARKET CAP
--
P/E (TTM)
-0.0010
1D
5D
1M
3M
1Y
5Y
1D
Surrozen Inc. Director and 10% Owner Tim Kutzkey Reports Acquisition of Common Shares
Reuters · 3d ago
Weekly Report: what happened at SRZNW last week (1124-1128)?
Weekly Report · 5d ago
Surrozen to Present at Upcoming Healthcare Investor Conferences
Reuters · 11/25 21:05
Weekly Report: what happened at SRZNW last week (1117-1121)?
Weekly Report · 11/24 09:30
Column Group Entities Report Acquisition of Surrozen Inc. Common Shares
Reuters · 11/18 00:16
Weekly Report: what happened at SRZNW last week (1110-1114)?
Weekly Report · 11/17 09:30
Surrozen Inc. Files Initial Statement of Beneficial Ownership for Chief Financial Officer Andrew Pedrum Maleki
Reuters · 11/13 21:15
Surrozen Grants Stock Options to New CFO Under 2025 Equity Inducement Plan
Reuters · 11/12 22:02
More
About SRZNW
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen’s SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.

Webull offers Surrozen Inc stock information, including NASDAQ: SRZNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRZNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRZNW stock methods without spending real money on the virtual paper trading platform.